Grade: Pharmaceutical Grade

Factory Location: Shandong

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 100kg

Contract Manufacturing: CRO,CMO

Packaging Information: 5kg/drum

Delivery Lead Time: 10days

Sample Provided: yes

Payment Terms: T/T

Product Name:    PARECOXIB SODIUM

Synonyms:    Parecoxib sodium (Intermediate in China ONLY);N-[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL)PHENYLSULFONYL]PROPIONAMIDE, SODIUM SALT;Parecoxib sodiuM salt;Dynastat;N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanaMide SodiuM Salt;Rayzon;SC 69124A;PropanaMide,N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-, sodiuM salt (1:1)

CAS:    198470-85-8

MF:    C19H19N2NaO4S

MW:    394.42

Melting point:   273-275°C

storage temp.:    Inert atmosphere,2-8°C

Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. A letter of non-approval for parecoxib was issued by the FDA in 2005.